Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.45 |
| ▸ | MCHR1 | Q99705 | 9/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2176011 | 0.87 | CNR2 (0.39) | MEN1ALDH1A1KMT2AKDM4ELMNA | |
| SCHEMBL2175566 | 0.87 | CNR2 (0.39) | MEN1ALDH1A1KMT2AKDM4ELMNA | |
| SCHEMBL2175223 | 0.85 | THRA (0.41) | MCHR1ALDH1A1KDM4E | |
| SCHEMBL2174906 | 0.83 | CNR2 (0.41) | ACHEMAOBSMN1; SMN2 | |
| SCHEMBL2179803 | 0.82 | MAPK14 (0.53) | MCHR1KCNH2MEN1ALDH1A1KMT2A | |
| SCHEMBL2174968 | 0.80 | CNR2 (0.39) | — | |
| SCHEMBL2178553 | 0.78 | MEN1 (0.40) | MEN1ALDH1A1KMT2A | |
| SCHEMBL2177989 | 0.75 | MEN1 (0.41) | MEN1ALDH1A1KMT2AKDM4ELMNA | |
| SCHEMBL2176608 | 0.74 | MAPK14 (0.45) | ALDH1A1LMNA | |
| SCHEMBL2178275 | 0.73 | TLR7 (0.50) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070135465-A1 | Fab I Inhibitor and Process for Preparing Same | CRYSTALGENOMICS, INC. (KR) | 2007-06-14 | — | — | US | claimed |
| US-7973060-B2 | Fab I inhibitor and process for preparing same | CRYSTALGENOMICS, INC. (KR) | 2011-07-05 | — | — | US | disclosed |
| US-20070135465-A1 | Fab I Inhibitor and Process for Preparing Same | CRYSTALGENOMICS, INC. (KR) | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135465-A1 | Fab I Inhibitor and Process for Preparing Same | TFPI, TFPI2, FCGRT | LTA4H 2956/4885MCHR1 4586/4885KCNH2 1674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.